|
Number
|
29
|
59
|
76
|
–
|
|
Age (years)
|
68 (66–75)
|
71 (66–78)
|
71 (61–78)
|
0.497
|
|
Male, n (%)
|
18 (62.1 %)
|
32 (54.2 %)
|
37 (48.7 %)
|
0.458
|
|
WBC (×109/L)
|
6.9 (5.6–7.9)
|
13.3 (10.9–17.8)
|
14.9 (11.8–17.2)
|
<0.001
|
|
Lymphocyte (×109/L)
|
2.8 (2.4–3.1)
|
1.06 (0.73–1.63)
|
0.76 (0.54–1.07)
|
<0.001
|
|
SOFA score
|
0
|
5 (3–7)
|
11 (9–14)
|
<0.001
|
|
SAPS II
|
12 (12–15)
|
26 (24–32)
|
53 (46–60)
|
<0.001
|
|
Percentage of PD-1+/CD4+ T cells (%)
|
26.2 (23.2–29.9)
|
34.1 (28.4–44.4)
|
38.2 (29.2–47.7)
|
<0.001
|
|
MFI of PD-1 on CD4+ T cells
|
6.3 (5.8–6.8)
|
7.1 (5.2–9.2)
|
7.5 (6.0–9.4)
|
0.008
|
|
Percentage of PD-1+/CD8+ T cells (%)
|
22.6 (18.7–28.2)
|
31.6 (23.9–46.6)
|
36.5 (27.3–51.3)
|
<0.001
|
|
MFI of PD-1 on CD8+ T cells
|
5.9 (4.8–6.6)
|
6.4 (4.2–7.5)
|
6.6 (4.9–8.4)
|
0.181
|
|
Percentage of PD-L1+/CD4+ T cells (%)
|
18.2 (12.3–22.6)
|
21.5 (16.5–30.5)
|
21.0 (9.3–30.6)
|
0.021
|
|
MFI of PD-L1 on CD4+ T cells
|
1.8 (1.6–2.2)
|
1.8 (1.6–2.6)
|
1.8 (1.5–2.0)
|
0.230
|
|
Percentage of PD-L1+/CD8+ T cells (%)
|
22.6 (17.1–26.2)
|
18.8 (14.9–37.6)
|
19.5 (10.3–37.4)
|
0.645
|
|
MFI of PD-L1 on CD8+ T cells
|
1.5 (1.4–1.7)
|
1.6 (1.2–2.1)
|
1.5 (1.4–1.8)
|
0.596
|
|
Percentage of monocytes expressing PD-L1 (%)
|
12.9 (10.4–15.3)
|
29.2 (12.1–43.9)
|
35.9 (20.4–54.7)
|
<0.001
|
|
MFI of PD-L1 on monocytes
|
3.4 (3.0–3.9)
|
4.5 (2.2–7.5)
|
8.3 (7.7–9.7)
|
<0.001
|
|
Type of infection, n (%)
| | | |
|
Pneumonia
|
0
|
30 (50.8 %)
|
41 (53.9 %)
|
0.731
|
|
IAI
|
0
|
7 (11.8 %)
|
11 (14.5 %)
|
0.658
|
|
CNSI
|
0
|
5 (8.5 %)
|
6 (7.9 %)
|
0.903
|
|
USI
|
0
|
17 (28.8 %)
|
18 (23.7 %)
|
0.500
|
|
Number of comorbidities
| | | |
|
≥1, n (%)
|
0
|
11 (18.6 %)
|
39 (51.3 %)
|
<0.001
|
|
28-day mortality, n (%)
|
0
|
10 (16.9 %)
|
27 (35.5 %)
|
0.016
|
